Back to search

University of Crete (UOC)

Διερεύνηση του ρόλου της ακτιβίνης στα αποφρακτικά νοσήματα των αεραγωγών

Abstract

dc:description

Activin A is a member of the TGF-β superfamily and is a key factor in airway inflammation. This protein and its binding protein, Follistatin, are widely expressed and their production is increased in many acute and chronic inflammatory conditions. Increasing evidence implicates activin A in the process of airway remodeling. The synthesis and release of activin is activated by inflammatory cytokines, Toll-like receptor ligands, and oxidative stress. Activin interacts with heterodimeric serine/threonine kinase receptor complexes to activate SMAD transcription factors and MAP kinase signaling pathways, which mediate inflammation, stress, and immunity. Activin-A can promote inflammation by activating the production of inflammatory mediators such as interleukins IL-1β, IL-6, TNF, and NO (1, 2). However, other studies show the opposite, that activin can inhibit inflammation. Clearly, the regulation of the immunoregulatory effect of Activin A is complex and dependent on anatomical location, cell type, and phase of the immune response. It has also been found that overexpression of Activin A in mouse lungs leads to lung pathology similar to that of patients with ALI/ARDS (3). Activin A is overexpressed in bronchoalveolar lavage of patients with ARDS at levels comparable to those produced in animal models. Activin A, in terms of its actions in respiratory physiology, appears to have a role in regulating surfactant synthesis and in the development of a procoagulant state. Therapeutic neutralization of activin A attenuates the pathology caused by ectopic or endogenous expression of activin A, which strongly suggests that activin A inhibitors may provide therapeutic benefit in patients with ALI/ARDS. However, the studies that have been conducted so far are only in experimental animals in vitro. Further research is required to study this molecule and to document its role in the pathophysiology of obstructive airway diseases in vivo.Our aim was to determine the levels of Activin expression in patients with COPD, ACO and Asthma at different time points for each patient, both during periods of disease exacerbation and at rest.We hypothesized that finding the expression levels of activin in sputum and blood serum of patients with COPD and patients with Asthma and ACO, at specific times in the course of the disease would allow us to identify: A. The exact expression of activin in the natural course of each disease separately (in exacerbation and at rest). B. To distinguish any differences/similarities between the diseases. C. To determine possible biological indicators of severity of exacerbation or even prognosis of the natural course of the above diseases. Our study included 54 patients in total, aged fourteen years and older, former and current smokers, who were hospitalized at the Pulmonary Clinic of the Heraklion University Hospital due to exacerbation of COPD, ACO or exacerbation of Bronchial Asthma. All subjects underwent routine pulmonary function tests, which included: pre- and post-bronchodilator spirometry, static volume measurements, as well as carbon monoxide diffusion capacity measurements, arterial blood gases, and chest X-ray. Age, height, weight, sex, and comorbidities were recorded. The type and severity of exacerbation, as well as the frequency of exacerbations of the disease in the last 2 years before entry into the study were recorded. Written informed consent was obtained from all patients participating in the study. Spontaneous sputum and peripheral blood were collected from each patient on the 1st day of exacerbation, on the day of discharge from the hospital, 1 month and 4 months after the exacerbation, if at rest, otherwise at each subsequent exacerbation. Although the collection of sputum samples was spontaneous, given the good repeatability of the procedure in each collection as well as the fact that at least four samples were collected in the same way in each patient at defined time periods, they ensure satisfactory sensitivity and specificity of our study samples. The sputum was centrifuged immediately and following a certified protocol, both the supernatant and the underlying part of the samples were stored in separate containers at -80 degrees Celsius. A peripheral blood sample was also taken from each patient, which was centrifuged and the supernatant was stored in eppedorf bottles at -80 degrees Celsius until the activin measurement was performed. In case of a new exacerbation and hospitalization of a patient at any time point from the 1st exacerbation within the total follow-up period, sputum and blood serum samples were collected again and new activin values ​​were measured. The maximum number of new exacerbations recorded for each patient was set at four. Activin levels were measured in the sputum and peripheral blood of the patients using the ELISA method, at four different time points per patient (1st day of exacerbation, day of discharge from the hospital, 1 and 3 months later at regular follow-up). The above findings were correlated with individual history, comorbidities, risk of exacerbations and results of lung function tests and we are now in search of the first correlations of activin levels with the above data.Pooled analyses showed that Activin A levels in sputum samples are significantly higher during exacerbation and then decrease after 4 months in both stable COPD (p = 0.013) and asthma (p = 0.016) or ACOS (p = 0.004), while in COPD patients who experienced at least one new exacerbation during this time period, Activin A levels in sputum remained similar at all time points of the study. In contrast, Activin A levels in serum of patients do not significantly decrease after exacerbation but rather increase during the 1 and 4 month reference periods (t1) in COPD and ACO. Overall, Activin A levels did not show significant differences between the COPD, asthma and ACO groups at any time point of the study in sputum or serum. However, baseline Activin A levels in sputum at the 4-month time point were significantly higher in COPD patients with at least one exacerbation compared to COPD patients without a new exacerbation (p = 0.033), with asthma (p = 0.013) or with ACO (p = 0.005). In conclusion, we can say based on our results that sputum Activin A levels increase during acute exacerbation in patients with chronic obstructive pulmonary diseases, while remaining elevated in serum even at baseline.

Degree

thesis:*
Grantor dc:publisher
University of Crete (UOC)
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Chatziantoniou, Argyro
  • Χατζηαντωνίου, Αργυρώ

Subjects

dc:subject × 13

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/61901

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Chatziantoniou, Argyro; Χατζηαντωνίου, Αργυρώ. Διερεύνηση του ρόλου της ακτιβίνης στα αποφρακτικά νοσήματα των αεραγωγών. University of Crete (UOC), 2026. http://hdl.handle.net/10442/hedi/61901